More Articles
The world is in the throes of an atrial fibrillation (AFib) pandemic, one that could potentially get worse in the years ahead due to population growth, economic hardships and rigid resource limitations.
The most effective way to…
Cardiologists and imaging specialists at Amsterdam University Medical Center (AUMC) have performed the world’s first ventricular ablation procedure guided by real-time MRI images.
LUMA Vision, a medical device company based out of Ireland and Germany, has received U.S. Food and Drug Administration (FDA) clearance for its new catheter-based visualization technology designed to help…
EBR Systems, a California-based medtech company, has gained U.S. Food and Drug Administration (FDA) approval for its innovative wireless pacing device for heart failure, the…
Just a week after taking office as the new American College of Cardiology (ACC) President, Christopher Kramer, MD, FACC, was in Washington, D.C.,…
CardioVia, an Israeli MedTech company, has gained U.S. Food and Drug Administration (FDA) clearance for its ViaOne technology designed to help clinicians reach the…
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/media_image/public/2024-09/istock-1209664264.jpg.webp?itok=FbSiOdtK)
Outpatient cardiology practices that participate in an accountable care organization (ACO) as part of the Medicare Shared Savings Program (MSSP) do not experience immediate improvements in the quality of care they provide, according to new…
The Heart Rhythm Society (HRS) has established is own legislative advocacy group Heart Rhythm Advocates (HRA), which has begun operations in Washington,…
The U.S. Food and Drug Administration (FDA) has informed Milestone Pharmaceuticals that it is not approving etripamil, the company’s new nasal spray for heart rhythm issues, at this time.
Etripamil…
Abbott has received CE mark approval in Europe for its new Volt Pulsed Field Ablation (PFA) System…
Exposure to scatter radiation and orthopedic issues related to years of wearing lead aprons during long EP procedures has led electrophysiologists to seek out new ways to reduce the need for angiographic X-ray. The Texas Cardiac Arrhythmia…
Advancements in radiofrequency (RF) catheter ablation technology have been incremental over the past 30 years in efforts to improve safety, procedural efficiency and patient outcomes. While some newer technologies have gained a lot of attention…
The Amplatzer Amulet Left Atrial Appendage Occluder (LAAO) from Abbott is safe and effective a full five years after treatment, according to new data published in the Journal of the American College of Cardiology.[1]
The study’s…
Advanced artificial intelligence (AI) algorithms could help cardiologists identify atrial fibrillation (AFib) patients on direct oral anticoagulants (DOACs) who face…
Small pacemakers built specifically for infants are both safe and effective, according to a new analysis published in Circulation: Arrhythmia and Electrophysiology.[1]
“There are two challenges with placing a pacemaker in a small…
The U.S. Food and Drug Administration (FDA) has announced a new recall for the ablation catheters associated with Johnson & Johnson MedTech’s Varipulse pulsed field ablation (PFA) system. No devices need to…
Kestra Medical Technologies, a Washington-based medtech company known for its wearable heart monitors and defibrillators, is going public on the Nasdaq Global Select Market under the ticker symbol KMTS.
The company intends to sell 10…
According to the U.S. Food and Drug Administration (FDA), safety issues with certain Boston Scientific pacemakers are significant enough that the situation has been categorized as a a Class I recall. This means…
Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse pulsed field ablation (PFA) system after previously putting cases on hold to review reports of patient complications. The Varipulse PFA system works as intended, the…
Researchers have developed a new artificial intelligence (AI) algorithm that can identify atrial fibrillation (AFib) patients who may benefit from left atrial…
Novartis has agreed to acquire Boston-based Anthos Therapeutics for up to $3.1 billion. The deal includes an upfront payment of $925 million and $2.15 billion in additional payments based on certain regulatory and commercial milestones.
…